STOCKHOLM--(BUSINESS WIRE)--Regulatory News: Diamyd Medical AB (STO:DIAM.B)(Pink Sheets:DMYDY) THE YEAR IN BRIEF - 4-year follow-up of type 1 diabetes patients included in a Phase II study with the drug candidate Diamyd® showed a clear positive trend.
